Chongqing Lummy Pharmaceutical
Chongqing Lummy Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of pharmaceutical products in China. It provides anti-tumor, anti-inflammatory, antibacterial, digestive, anti-virus, blood system, cardiovascular system, acid-base balance nutritional medicine, endocrine system drugs, tumor adjuvant medication, antifungal, and opioid receptor antagonists. Chon… Read more
Chongqing Lummy Pharmaceutical (300006) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.008x
Based on the latest financial reports, Chongqing Lummy Pharmaceutical (300006) has a cash flow conversion efficiency ratio of -0.008x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-14.90 Million) by net assets (CN¥1.85 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Chongqing Lummy Pharmaceutical - Cash Flow Conversion Efficiency Trend (2006–2024)
This chart illustrates how Chongqing Lummy Pharmaceutical's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Chongqing Lummy Pharmaceutical Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Chongqing Lummy Pharmaceutical ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shanghai Xinpeng Industry Co Ltd
SHE:002328
|
0.059x |
|
Chengdu Galaxy Magnets
SHE:300127
|
0.065x |
|
Shen Ma Industry Co Ltd
SHG:600810
|
0.029x |
|
Rogers Sugar Inc
PINK:RSGUF
|
0.006x |
|
Drägerwerk AG & Co. KGaA
PINK:DGWPF
|
0.050x |
|
TOUR EIFFEL INH. EO 5
F:UVA
|
N/A |
|
Topdanmark AS
PINK:TPDKY
|
-0.107x |
|
EQ Resources Ltd
AU:EQR
|
-0.351x |
Annual Cash Flow Conversion Efficiency for Chongqing Lummy Pharmaceutical (2006–2024)
The table below shows the annual cash flow conversion efficiency of Chongqing Lummy Pharmaceutical from 2006 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥1.88 Billion | CN¥185.03 Million | 0.098x | +155.72% |
| 2023-12-31 | CN¥2.12 Billion | CN¥81.53 Million | 0.038x | +46.92% |
| 2022-12-31 | CN¥2.18 Billion | CN¥57.13 Million | 0.026x | -46.58% |
| 2021-12-31 | CN¥2.21 Billion | CN¥108.28 Million | 0.049x | -73.15% |
| 2020-12-31 | CN¥1.23 Billion | CN¥224.54 Million | 0.182x | +30.35% |
| 2019-12-31 | CN¥1.65 Billion | CN¥231.30 Million | 0.140x | +6.75% |
| 2018-12-31 | CN¥1.72 Billion | CN¥225.89 Million | 0.131x | +267.72% |
| 2017-12-31 | CN¥1.72 Billion | CN¥61.39 Million | 0.036x | -52.53% |
| 2016-12-31 | CN¥1.67 Billion | CN¥125.66 Million | 0.075x | +599.18% |
| 2015-12-31 | CN¥1.69 Billion | CN¥-25.41 Million | -0.015x | +69.04% |
| 2014-12-31 | CN¥1.02 Billion | CN¥-49.38 Million | -0.049x | -173.18% |
| 2013-12-31 | CN¥1.13 Billion | CN¥74.70 Million | 0.066x | +159.29% |
| 2012-12-31 | CN¥710.51 Million | CN¥18.18 Million | 0.026x | +42.56% |
| 2011-12-31 | CN¥660.17 Million | CN¥11.85 Million | 0.018x | -73.23% |
| 2010-12-31 | CN¥561.59 Million | CN¥37.66 Million | 0.067x | -5.73% |
| 2009-12-31 | CN¥525.08 Million | CN¥37.35 Million | 0.071x | -43.18% |
| 2008-12-31 | CN¥137.79 Million | CN¥17.25 Million | 0.125x | -37.70% |
| 2007-12-31 | CN¥107.91 Million | CN¥21.68 Million | 0.201x | +66.59% |
| 2006-12-31 | CN¥64.39 Million | CN¥7.77 Million | 0.121x | -- |